AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16192774 — intervention group
Group type: COMPARATOR
Intervention: Intravenous treatment (lidocaine-sufentanil-clonidine)
Number of subjects: 85
Study 16192774 — intervention group
Group type: COMPARATOR
Intervention: Postoperative epidural treatment (intravenous-epidural)
Number of subjects: 85
Study 16192774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative epidural treatment (epidural-epidural and epidural-intravenous)
Number of subjects: 85
Study 12519409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine oestrogens
Number of subjects: 2
Study 12519409 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17 beta‐oestradiol
Number of subjects: 2
Study 12519409 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2
Study 12519409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17 beta‐oestradiol followed by sequential oestrogen‐progestogen HRT (17 beta‐oestradiol and dydrogesterone)
Number of subjects: 2
Study 10759926 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A, 100 units, diluted in 1 mL of saline
Number of subjects: 26
Study 10759926 — intervention group
Group type: COMPARATOR
Intervention: Saline (1 mL)
Number of subjects: 26
Study 8641826 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of oral zinc sulfate once daily for 24 months
Number of subjects: 112
Study 8641826 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 24 months
Number of subjects: 112
Study 8641826 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 1507320 — intervention group
Group type: EXPERIMENTAL
Intervention: 67Ga-citrate
Number of subjects: 15
Study 1507320 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-oxine
Number of subjects: 15
Study 30922341 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal health CHW program
Number of subjects: 2329
Study 30922341 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2329
Study 28911062 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF-E (cisplatin and docetaxel 75mg/m2 on day 1 followed by 5-FU 750mg/m2/day as a continuous infusion on days 1-5 plus cetuximab at a loading dose of 400mg/m2 followed by a weekly dose of 250mg/m2)
Number of subjects: 47
Study 28911062 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 40mg/m2
Number of subjects: 47
Study 28911062 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin, AUC of 1.5mg/ml/min
Number of subjects: 47
Study 28911062 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (70Gy over 7 weeks in 2Gy fractions) with weekly cetuximab
Number of subjects: 47
Study 26031148 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate monotherapy (5-20 mg weekly)
Number of subjects: 63
Study 24106872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine HCl (300 mg)
Number of subjects: 61
Study 24106872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis (THC)
Number of subjects: 61
Study 24106872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 21212421 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 0
Study 21212421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20152899 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrifen (100 microg/h)
Number of subjects: 30
Study 20152899 — intervention group
Group type: COMPARATOR
Intervention: Durogesic DTrans (100 microg/h)
Number of subjects: 30
Study 17525698 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a splint for 12 weeks
Number of subjects: 14
Study 17525698 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical release
Number of subjects: 14
Study 15741251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix (selective GnRH-receptor antagonist)
Number of subjects: 18
Study 15741251 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study 11940323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty
Number of subjects: 69
Study 11940323 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty
Number of subjects: 69
Study 9804024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implants (CI), post-operative period
Number of subjects: 0
Study 9804024 — intervention group
Group type: COMPARATOR
Intervention: Non-CI group
Number of subjects: 0
Study 7614643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg plus sodium citrate
Number of subjects: 25
Study 7614643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg plus sodium citrate
Number of subjects: 25
Study 7614643 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate alone
Number of subjects: 25
Study 2693542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (LFLX) 600 mg/day for 5 days
Number of subjects: 169
Study 2693542 — intervention group
Group type: COMPARATOR
Intervention: Pipemidic acid (PPA) 2000 mg/day for 5 days
Number of subjects: 169
Study 2693542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (LFLX)
Number of subjects: 169
Study 2693542 — intervention group
Group type: COMPARATOR
Intervention: Pipemidic acid (PPA)
Number of subjects: 169
Study 38806 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term neuroleptic treatment (individually adjusted dosage)
Number of subjects: 0
Study 38806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38806 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term neuroleptic treatment
Number of subjects: 0
Study 31537559 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised structured cognitive rehabilitation
Number of subjects: 50
Study 31537559 — intervention group
Group type: COMPARATOR
Intervention: Best patient‐centred care for attention disorders
Number of subjects: 50
Study 28935470 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5 (pentavalent live human-bovine reassortant rotavirus vaccine)
Number of subjects: 4040
Study 28935470 — intervention group
Group type: EXPERIMENTAL
Intervention: RV5
Number of subjects: 4040
Study 28935470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4040
Study 25349227 — intervention group
Group type: EXPERIMENTAL
Intervention: Transseptal catheterization for atrial fibrillation ablation
Number of subjects: 13
Study 23138396 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acethyl-cysteine (NAC) 600 mg twice daily the day before and the day of the procedure plus 154 mmol NaHCO3 solution (B0) at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h (BN group)
Number of subjects: 123
Study 23138396 — intervention group
Group type: COMPARATOR
Intervention: 154 mmol NaHCO3 solution (B0) at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h (B0 group)
Number of subjects: 123
Study 23138396 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acethyl-cysteine (NAC) as above plus 154 mmol NaCl solution at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h (SN group)
Number of subjects: 123
Study 23138396 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acethyl-cysteine (NAC)
Number of subjects: 123
Study 23138396 — intervention group
Group type: COMPARATOR
Intervention: No NAC
Number of subjects: 123
Study 21636073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sixteen weeks of progressive resistance training
Number of subjects: 64
Study 19002646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using two diode laser probes (660 nm, 6.2 J/cm², 6 min, continuous wave; 890 nm, 1 J/cm², 10 min, 1,500 Hz)
Number of subjects: 16
Study 19002646 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo treatment, similar procedure without irradiation)
Number of subjects: 16
Study 16311275 — intervention group
Group type: EXPERIMENTAL
Intervention: 3H1
Number of subjects: 630
Study 16311275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study 15638022 — intervention group
Group type: EXPERIMENTAL
Intervention: Snodgrass urethroplasty
Number of subjects: 79
Study 15638022 — intervention group
Group type: COMPARATOR
Intervention: Mathieu urethroplasty
Number of subjects: 79
Study 10786260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist outreach program with academic detailing on ACE inhibitors and angiotensin II-receptor inhibitors for CHF.
Number of subjects: 0
Study 10786260 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians not receiving the outreach program).
Number of subjects: 0
Study 10786260 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with digoxin and furosemide identified as CHF patients.
Number of subjects: 0
Study 10786260 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with an ACE inhibitor for CHF.
Number of subjects: 0
Study 9326126 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic
Number of subjects: 0
Study 9326126 — intervention group
Group type: COMPARATOR
Intervention: General anaesthetic
Number of subjects: 0
Study 8353101 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + levamisole
Number of subjects: 0
Study 8353101 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative local chemotherapy (intraportal)
Number of subjects: 0
Study 8353101 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative radiation therapy with chemotherapy
Number of subjects: 0
Study 8353101 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + MeCCNU +/‐ oncovin
Number of subjects: 0
Study 8353101 — intervention group
Group type: COMPARATOR
Intervention: Single agent systemic chemotherapy
Number of subjects: 0
Study 8353101 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiation therapy
Number of subjects: 0
Study 2874738 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-DTP vaccine
Number of subjects: 60
Study 30118241 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 27
Study 30118241 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with vitamin C (EX + Vit.C)
Number of subjects: 27
Study 30118241 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 27
Study 25721305 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 66
Study 25721305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 66
Study 24916996 — intervention group
Group type: EXPERIMENTAL
Intervention: New sample of 800 cases after data rectification
Number of subjects: 800
Study 24916996 — intervention group
Group type: COMPARATOR
Intervention: Initial sample of 840 cases from Multan
Number of subjects: 800
Study 21538700 — intervention group
Group type: EXPERIMENTAL
Intervention: bihemispheric transcranial direct current stimulation and simultaneous physical/occupational therapy for five consecutive days
Number of subjects: 15
Study 20541949 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil®
Number of subjects: 299
Study 20541949 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 299
Study 18534326 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 48
Study 18534326 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (sham acupuncture)
Number of subjects: 48
Study 18534326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 16225490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg
Number of subjects: 183
Study 16225490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 20 mg
Number of subjects: 183
Study 16225490 — intervention group
Group type: COMPARATOR
Intervention: Oral esomeprazole 40 mg
Number of subjects: 183
Study 16225490 — intervention group
Group type: COMPARATOR
Intervention: Oral esomeprazole 20 mg
Number of subjects: 183
Study 16225490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole
Number of subjects: 183
Study 16225490 — intervention group
Group type: COMPARATOR
Intervention: Oral esomeprazole
Number of subjects: 183
Study 12481473 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 549
Study 12481473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study 10407906 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast rate of digit presentation (100 msec. interstimulus interval)
Number of subjects: 139
Study 10407906 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow rate of digit presentation (1,300 msec. interstimulus interval)
Number of subjects: 139
Study 10407906 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate time estimation
Number of subjects: 139
Study 10407906 — intervention group
Group type: EXPERIMENTAL
Intervention: List length of 25 digits
Number of subjects: 139
Study 10407906 — intervention group
Group type: EXPERIMENTAL
Intervention: List length of 50 digits
Number of subjects: 139
Study 7756468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritipenem acoxil (500 mg three times daily)
Number of subjects: 281
Study 7756468 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (200 mg twice daily)
Number of subjects: 281
Study 7756468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritipenem acoxil
Number of subjects: 281
Study 7756468 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 281
Study 2144788 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18 mg/kg ondansetron (high dose)
Number of subjects: 36
Study 2144788 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg ondansetron (low dose)
Number of subjects: 36
Study 7286585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabernet Sauvignon (mean ethanol concentration = 9500 mg/dl)
Number of subjects: 10
Study 7286585 — intervention group
Group type: COMPARATOR
Intervention: Low-alcohol Cabernet Sauvignon (mean ethanol concentration = 1312 mg/dl)
Number of subjects: 10
Study 7286585 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine (with solid food)
Number of subjects: 10
Study 7286585 — intervention group
Group type: COMPARATOR
Intervention: Low-alcohol wine (without solid food)
Number of subjects: 10
Study 29071331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib, 600 mg daily
Number of subjects: 4140
Study 29071331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4140
Study 26694846 — intervention group
Group type: EXPERIMENTAL
Intervention: 18‐wk supervised exercise program
Number of subjects: 33
Study 26694846 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 33
Study 24895566 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior upper body exercise (4 sets of biceps curls)
Number of subjects: 11
Study 24895566 — intervention group
Group type: COMPARATOR
Intervention: No prior upper body exercise (control)
Number of subjects: 11
Study 24895566 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior upper body exercise
Number of subjects: 11
Study 22537990 — intervention group
Group type: EXPERIMENTAL
Intervention: Healive (one dose)
Number of subjects: 303
Study 22537990 — intervention group
Group type: COMPARATOR
Intervention: Havrix (one dose)
Number of subjects: 303
Study 22537990 — intervention group
Group type: EXPERIMENTAL
Intervention: Healive (two doses)
Number of subjects: 303
Study 22537990 — intervention group
Group type: COMPARATOR
Intervention: Havrix (two doses)
Number of subjects: 303
Study 22537990 — intervention group
Group type: EXPERIMENTAL
Intervention: Healive-Havrix (two doses)
Number of subjects: 303
Study 22537990 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix-Healive (two doses)
Number of subjects: 303
Study 20445430 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention for ankle reflex examination skills
Number of subjects: 22
Study 20445430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 17566515 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucan solution nasal spray
Number of subjects: 100
Study 17566515 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study 17566515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study 15683490 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (estradiol plus norethisterone acetate, n = 13)
Number of subjects: 40
Study 15683490 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT (estradiol, n = 14)
Number of subjects: 40
Study 15683490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 40
Study 11996634 — intervention group
Group type: COMPARATOR
Intervention: Newer antidepressant medications (including serotonergic antidepressants and buspirone)
Number of subjects: 0
Study 11996634 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines and tricyclic antidepressants (TCAs)
Number of subjects: 0
Study 10488969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU daily for 8 weeks)
Number of subjects: 28
Study 10488969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8730557 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy plus drug resistance modifying agents such as cyclosporins
Number of subjects: 0
Study 8730557 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study 1664629 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% prilocaine plus sodium bicarbonate
Number of subjects: 30
Study 1664629 — intervention group
Group type: COMPARATOR
Intervention: 1% prilocaine
Number of subjects: 30
Study 6861873 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release (CR) formulation of indomethacin 75 mg (Indocid‐Retard) given once daily
Number of subjects: 14
Study 6861873 — intervention group
Group type: COMPARATOR
Intervention: Conventional 25 mg indomethacin capsule (Indocid) given 3 times daily
Number of subjects: 14
Study 31730506 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions (exercise, medication, nutritional management, improving safety of the local environment)
Number of subjects: 0
Study 31730506 — intervention group
Group type: EXPERIMENTAL
Intervention: Programs aimed at preventing hospital inpatient falls
Number of subjects: 0
Study 31730506 — intervention group
Group type: COMPARATOR
Intervention: Hospital inpatient falls
Number of subjects: 0
Study 29381666 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus MPA (2.5 mg/d)
Number of subjects: 18015
Study 29381666 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/d)
Number of subjects: 18015
Study 29381666 — intervention group
Group type: COMPARATOR
Intervention: Placebo for CEE plus MPA
Number of subjects: 18015
Study 29381666 — intervention group
Group type: COMPARATOR
Intervention: Placebo for CEE
Number of subjects: 18015
Study 29381666 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus MPA (2.5 mg/d) postintervention
Number of subjects: 18015
Study 29381666 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/d) postintervention
Number of subjects: 18015
Study 26786744 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice HIV test offers
Number of subjects: 4800
Study 26786744 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out HIV test offers
Number of subjects: 4800
Study 26786744 — intervention group
Group type: COMPARATOR
Intervention: Opt-in HIV test offers
Number of subjects: 4800
Study 26786744 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms (opt-in, active choice, opt-out)
Number of subjects: 4800
Study 26039906 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost glass ionomer cement (GIC)
Number of subjects: 437
Study 26039906 — intervention group
Group type: COMPARATOR
Intervention: High-cost glass ionomer cement (GIC)
Number of subjects: 437
Study 22318530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramadan‐intermittent‐fasting (RIF) during the second week of Ramadan (SWR)
Number of subjects: 10
Study 22318530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramadan‐intermittent‐fasting (RIF) during the fourth week of Ramadan (ER)
Number of subjects: 10
Study 22318530 — intervention group
Group type: COMPARATOR
Intervention: Wingate test at 07:00 (morning)
Number of subjects: 10
Study 22318530 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingate test at 17:00 (evening) during Ramadan
Number of subjects: 10
Study 19508679 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg rhTSH
Number of subjects: 9
Study 19508679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg rhTSH
Number of subjects: 9
Study 19508679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg rhTSH
Number of subjects: 9
Study 18586811 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrical stimulation
Number of subjects: 18
Study 18586811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16043847 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA-Standard (SS) visual field testing
Number of subjects: 243
Study 16043847 — intervention group
Group type: COMPARATOR
Intervention: Full-threshold (FT) visual field testing
Number of subjects: 243
Study 12417271 — intervention group
Group type: COMPARATOR
Intervention: LpE:A-I:A-II
Number of subjects: 2
Study 12417271 — intervention group
Group type: COMPARATOR
Intervention: LpE:A-II
Number of subjects: 2
Study 12417271 — intervention group
Group type: COMPARATOR
Intervention: LpE:A-I
Number of subjects: 2
Study 12417271 — intervention group
Group type: EXPERIMENTAL
Intervention: LpE
Number of subjects: 2
Study 12417271 — intervention group
Group type: COMPARATOR
Intervention: apoA-I on LpA-I:A-II
Number of subjects: 2
Study 12417271 — intervention group
Group type: COMPARATOR
Intervention: apoA-I on LpA-I
Number of subjects: 2
Study 10466902 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaguchek monitor
Number of subjects: 30
Study 10466902 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTime Microcoagulation System
Number of subjects: 30
Study 10466902 — intervention group
Group type: COMPARATOR
Intervention: Survey preference for INR determination methods
Number of subjects: 30
Study 7492829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 1776335 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (16 mg, slow-release formulation)
Number of subjects: 12